转移性肾癌运用自体树突状细胞联合细胞因子诱导的杀伤细胞的临床治疗效果
|
摘要
目的观察运用自体树突状细胞(DC)联合细胞因子诱导的杀伤细胞(CIK细胞)治疗转移性肾癌的效果。方法搜集本院60例转移性肾癌患者资料,入选患者均为可以用于评估的有效病灶,均采用DC联合CIK细胞治疗。结果转移性肾癌运用DC联合CIK细胞治疗后:完全缓解2例(3.3%)、部分缓解21例(35.0%)、疾病稳定28例(46.7%)、疾病进展9例(15.0%),疾病控制率为85%,客观缓解率为38.3%,总生存率为82.0%。结论 DC联合CIK细胞临床价值较高,治疗转移性肾癌临床效果较好。
objective Clinical effect of autologous dendritic cells(DC) combined with cytokine induced killer cells in metastatic renal cell carcinoma(RCC). Method The data of 60 patients with metastatic renal cancer were collected in our hospital. All the patients were used to evaluate the effective focus,and the DC vaccine combined with cytokine induced killer cells(CIK cells). Result After the treatment of CIK cells induced by DC vaccine combined with cytokines,2 cases(3. 3%),21 cases of remission(35%),28 cases of disease stability(46.7%)and 9 cases of disease progression(15%)were completely relieved after the treatment of metastatic renal cell carcinoma, and the control rate of disease was 85%,the objective remission rate was 38. 3% and the total survival rate was 82%. Conclusion DC vaccine combined with cytokine induced CIK cells has higher clinical value and has better clinical effect in the treatment of metastatic renal cell carcinoma.
objective Clinical effect of autologous dendritic cells(DC) combined with cytokine induced killer cells in metastatic renal cell carcinoma(RCC). Method The data of 60 patients with metastatic renal cancer were collected in our hospital. All the patients were used to evaluate the effective focus,and the DC vaccine combined with cytokine induced killer cells(CIK cells). Result After the treatment of CIK cells induced by DC vaccine combined with cytokines,2 cases(3. 3%),21 cases of remission(35%),28 cases of disease stability(46.7%)and 9 cases of disease progression(15%)were completely relieved after the treatment of metastatic renal cell carcinoma, and the control rate of disease was 85%,the objective remission rate was 38. 3% and the total survival rate was 82%. Conclusion DC vaccine combined with cytokine induced CIK cells has higher clinical value and has better clinical effect in the treatment of metastatic renal cell carcinoma.
引文
[1]张金超,杨岩丽,孙雪冬,等.自体树突细胞联合细胞因子诱导的杀伤细胞治疗转移性肾癌的疗效分析及随访观察[J].解放军医学杂志,2016,41(10):827-832.
[2]王宁,李明义,杨培谦,等.肾癌预后分析系统概述[J].中国医刊,2016,51(9):26-28.
[3]王媛,吴英,董丽,等.转移性肾癌的治疗新进展[J].临床误诊误治,2018,31(2):114-116.
[4]江卫星,寿建忠.转移性肾细胞癌免疫治疗的现状与进展[J].中华泌尿外科杂志,2017,38(7):555-558.
[5]张百红,岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志,2016,43(11):845-847.
[6]吴迪,付立业,李妍,等.自体抗原负载DC联合CIK对肾癌免疫治疗的实验研究[J].现代肿瘤医学,2017,25(24):3919-3923.
[7]Anguille S,Smits EL,Bryant C,et al.Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy[J].Pharmacol Rev,2015,67(4):731-753.
[8]刘波,陈伟,邓全红,等.自体细胞因子诱导的杀伤细胞回输对肾细胞癌根治术后患者T淋巴细胞亚群的影响[J].中国临床医生杂志,2017,45(9):54.
[9]许涛,景红霞,李林均,等.TACE、IMRT、HIFU联合DC-CIK治疗局部晚期原发性肝癌的效果[J].广东医学,2016,37(12):1846-1849.
[10]谢云青,陈莉,杨建伟,等.DC-CIK细胞联合常规治疗对肾透明细胞癌患者的临床疗效[J].中国肿瘤生物治疗杂志,2017,24(6):665-669.
[11]Skowera A,de Jong EC,Schuitemaker JH,et al.Analysis of anthrax and plague biowarfare vaccine interactions with human monocytederived dendritic cells[J].Journal of Immunology,2005,175(11):7235-7243.
[2]王宁,李明义,杨培谦,等.肾癌预后分析系统概述[J].中国医刊,2016,51(9):26-28.
[3]王媛,吴英,董丽,等.转移性肾癌的治疗新进展[J].临床误诊误治,2018,31(2):114-116.
[4]江卫星,寿建忠.转移性肾细胞癌免疫治疗的现状与进展[J].中华泌尿外科杂志,2017,38(7):555-558.
[5]张百红,岳红云.实体瘤疗效评价标准简介[J].国际肿瘤学杂志,2016,43(11):845-847.
[6]吴迪,付立业,李妍,等.自体抗原负载DC联合CIK对肾癌免疫治疗的实验研究[J].现代肿瘤医学,2017,25(24):3919-3923.
[7]Anguille S,Smits EL,Bryant C,et al.Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy[J].Pharmacol Rev,2015,67(4):731-753.
[8]刘波,陈伟,邓全红,等.自体细胞因子诱导的杀伤细胞回输对肾细胞癌根治术后患者T淋巴细胞亚群的影响[J].中国临床医生杂志,2017,45(9):54.
[9]许涛,景红霞,李林均,等.TACE、IMRT、HIFU联合DC-CIK治疗局部晚期原发性肝癌的效果[J].广东医学,2016,37(12):1846-1849.
[10]谢云青,陈莉,杨建伟,等.DC-CIK细胞联合常规治疗对肾透明细胞癌患者的临床疗效[J].中国肿瘤生物治疗杂志,2017,24(6):665-669.
[11]Skowera A,de Jong EC,Schuitemaker JH,et al.Analysis of anthrax and plague biowarfare vaccine interactions with human monocytederived dendritic cells[J].Journal of Immunology,2005,175(11):7235-7243.